LPX TIIBD
Alternative Names: LPX-TIIBDLatest Information Update: 26 Apr 2023
At a glance
- Originator LAPIX Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 11 Apr 2023 Lapix Therapeutics plans a pivotal non-clinical study and dose optimization study for Inflammatory bowel disease (Lapix Therapeutics Pipeline, April 2023)
- 09 Apr 2023 Preclinical trials in Inflammatory bowel disease in USA (PO) (Lapix Therapeutics Pipeline, April 2023)
- 09 Apr 2023 Lapix Therapeutics plans a clinical trial for Inflammatory bowel disease in June 2024 (Lapix Therapeutics Pipeline, April 2023)